These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36777363)

  • 21. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
    Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
    Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn's Disease: Results from an Early Access Program in Brazil.
    Chebli JMF; Parra RS; Flores C; Moraes AC; Nones RB; Gomes TNF; Perdomo AMB; Scapini G; Zaltman C
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
    Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
    Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.
    Fumery M; Peyrin-Biroulet L; Nancey S; Altwegg R; Gilletta C; Veyrard P; Bouguen G; Viennot S; Poullenot F; Filippi J; Buisson A; Bozon A; Brazier F; Pouillon L; Flourie B; Boivineau L; Siproudhis L; Laharie D; Roblin X; Diouf M; Treton X
    J Crohns Colitis; 2020 Sep; ():. PubMed ID: 32898232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. USTEKINUMAB IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY.
    Castro PCS; Magro DO; Nones RB; Furlan TK; Miranda EF; Kotze PG
    Arq Gastroenterol; 2022; 59(4):501-507. PubMed ID: 36515346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
    Viola A; Muscianisi M; Macaluso FS; Ventimiglia M; Cappello M; Privitera AC; Magnano A; Pluchino D; Magrì G; Ferracane C; Mocciaro F; Garufi S; Giuffrida E; Costantino G; Fiocco G; Grova M; Guida L; Alibrandi A; Orlando A; Fries W;
    JGH Open; 2021 Mar; 5(3):364-370. PubMed ID: 33732883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
    Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
    Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn's disease: tertiary centers experience in Japan.
    Esaki M; Ihara Y; Tominaga N; Takedomi H; Tsuruoka N; Akutagawa T; Yukimoto T; Kawasaki K; Umeno J; Torisu T; Sakata Y
    Int J Colorectal Dis; 2023 Mar; 38(1):57. PubMed ID: 36856849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
    Af Björkesten CG; Ilus T; Hallinen T; Soini E; Eberl A; Hakala K; Heikura M; Jussila A; Koskela R; Koskinen I; Moilanen V; Nielsen C; Nieminen U; Nuutinen H; Heikkinen M; Suhonen UM; Tillonen J; Utriainen K; Vihriälä I; Wennerström C; Borsi A; Nissinen R; Koivunen MR; Sipponen T
    Eur J Gastroenterol Hepatol; 2020 Dec; 32(12):1507-1513. PubMed ID: 32868649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    MacDonald JK; Nguyen TM; Khanna R; Timmer A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab.
    Zhdanava M; Ding Z; Manceur AM; Muser E; Lefebvre P; Holiday C; Lafeuille MH; Pilon D
    Curr Med Res Opin; 2023 Apr; 39(4):533-543. PubMed ID: 36752586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.